Project budget3 801 252 €
ERDF amount2 280 751 €
The common challenge concerned by CoBra project is related to the cancer control plan.
The CoBra project is interested on technological innovation for diagnosis and treatment of localised cancers able to enhance the quality of life for patient and reduce the cancer mortality.
The CoBra project aims to improve the quality of both diagnosis and treatment of localized cancers, by developing innovative technology for biopsy and brachytherapy under MRI control.
- Prototype: to develop a new medical robot prototype for diagnosis and treatment of localized cancers by brachytherapy and biopsy under guidance of MRI. The main localizations are focussed on Prostate and other soft tissues. This prototype will contribute in enhancing the practice of the Brachytherapy in the 2 Seas region. At the end of the project, the concept should be tested on biological subjects, before a technological transfer in the region of the 2 Seas.
- Training: to initiate a training programme for practitioners and physicists on MRI based robotic brachytherapy and biopsy in the 2 Seas region.
- Study: to elaborate a map for targeted cancers dispersion in the region of 2 Seas. This allows estimating the optimal placement of the designed concept in the region of the 2 Seas according to the patient concentration.
- Network: to develop a network of SMEs and Start-up for technological transfer of the new designed concept.
Cross border approach
The fight against cancer is a plan that concerns cross-border countries. The 2 Seas region has complementary competences able to reach the overall objectives of the project. Without this cross-border cooperation, it is not feasible to realize this technological innovation. U-Lille (Fr) will contribute to the development of the robot in collaboration with a SME Demcon (Nl); UT-Delft (Nl) will develop specific needles under IRM control; U-Port. (UK) will work on the time optimization of the treatment plan and the cancer mapping in south of UK. COL (Fr) and NHS (UK) are referenced hospital in the 2 Seas region for the Brachytherapy practice, while Oncovet (Fr) will be a platform for principle proof of the concept for treatment of animal cancers. SATT-Nord (Fr) is a company specialized in the intellectual property of the technological innovation. Finally Eurasanté (Fr) will work on the cancer mapping in the continent and links to SMEs in the exploitation of the results of the project.
During 2019, the CoBra project progressed well on the development of the concept of the MR-robot for the biopsy and brachytherapy, with respect to the initial workplan.
After a first year (2018), intended to develop requirements and specifications on CoBra innovation, in partnership with industrials (intra or extra to the consortium), we began in 2019, the collaborative development of the concept. Clinical and scientific expertise have been provided by the clinical partners (NHS Portsmouth-PP9, Centre Oscar Lambret-PP2) to advice and commentary on developments across the project. These are discussed during the periodic technical meeting, organized by the LP every two weeks, on Friday at 12:00 AM. From technical point of view, multiple progresses have been reached, where a set up of automatic biopsy system that is able to take and automatically store up to 6 specimens has been developed by Demcon (PP6-PP10). The integration to a final prototype, coupled to the robot is under-discussion with the LP for 2020. Also, a steerable needle prototype has been designed by TU Delft-PP3 and tested in MR conditions at the regional Hospital in Lille, with the presence of the trajectory-planning algorithm developed by U. Portsmouth-PP4. A prototype of LDR-seeds delivery has been developed by UdLille (LP) and operated under MRI, due to a strong cooperation with Bebig company (new project observer). An MRI device model has been acquired by the LP, a part of the output 1 related to Common Diagnosis and Treatment Platform. Finally, preparation of MR images for the dose calculation in case of cancer treatment has been developed by PP2.
To describe the brachytherapy clinical practices, technologies and needs for prostate cancer care inside and outside the 2 seas Programme area, a questionnaire has been realized by EURASANTE (PP5) and sent to clinicians of cancer centres inside and outside the 2 seas region. In terms of intellectual property, a strategy for the project deliverables has been studied by SATT-Nord (PP7). Concerning the dissemination of the project results, project partners participated to various events within the UK and the continent and the organisation of CoBra Workshop during MEDFIT event in Lille.